D e s i g n
Randomized (allocation concealed*), blinded (clinicians, patients, and outcome assessors),* controlled trial with 90-day follow-up.
S e t t i n g 4 Canadian academic centers. P a t i e n t s 201 patients who were ≥ 18 years of age (mean age 55 y, 56% men) and had objectively confirmed acute VTE (deep venous thrombosis or pulmonary embolism). Exclusion criteria were a baseline international normalized ratio (INR) > 1.4, platelet count < 50 × 10 9 cells/mL, need for hospitalization, use of oral anticoagulant therapy in the previous 2 weeks, or high risk for major bleeding. 90-day follow-up was complete.
I n t e r v e n t i o n
Patients were allocated to warfarin induction with either a 10-mg (n = 104) or a 5-mg warfarin nomogram (n = 97). Treatment began with full-dose subcutaneous lowmolecular-weight heparin (LMWH) (dalteparin or tinzaparin) and continued daily for 5 days until the INR reached therapeutic levels (> 1.9). 
M a i n r e s u l t s
Analysis was by intention to treat. Patients in the 10-mg-nomogram group had a shorter mean time to a therapeutic INR and were more likely to have a therapeutic INR at day 5 than were patients in the 5-mg-nomogram group (Table) . The groups did not differ for rates of VTE, major bleeding, or death (Table) .
C o n c l u s i o n
In outpatients with venous thromboembolism, a warfarin nomogram using 10-mg loading doses was more effective than a warfarin nomogram using 5-mg loading doses. C o m m e n t a r y VTE is a common and potentially fatal disease that annually affects 2 persons per 1000 (1, 2) . Although advances in diagnostics and treatment have been made, much more work is needed to lessen the burden of this chronic disease. Recent work has focused on determining the optimal duration (3) and intensity of therapy (4) to prevent recurrent disease. Efforts to improve the ease and efficiency of management and patient convenience without sacrificing safety would be further advances. Newer therapies, such as LMWH, have shifted treatment of acute VTE to the outpatient setting where maximizing the efficiency and safety of warfarin loading could reduce the time needed to achieve a therapeutic INR. This could potentially be translated into cost savings if the overlap of heparin and warfarin therapies and the frequency of INR testing were minimized. Kovacs and colleagues' study attempted to maximize the efficiency of warfarin loading. As the authors rightly conclude, patients who require inpatient treatment are clinically different, and this nomogram may not be appropriate for them or other patients who require a lower loading dose. The trial's main strength was the 90-day follow-up, although the study was not powered to detect significant differences in the outcomes of recurrent VTE, major bleeding, or death. Thus, firm conclusions about the safety of the 10-mg nomogram cannot be made.
The 10-mg nomogram resulted in a therapeutic INR in less time and with fewer INR measurements. A formal cost analysis would have added significantly to the authors' findings. Nonetheless, Kovacs and colleagues should be applauded for conducting high-quality work to define "best practices" in the treatment and management of acute VTE.
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